Optimer Pharmaceuticals, Inc. (OPTR) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-58.2M
Depreciation and amortization	516.44K
Stock based compensation	7.12M
Issuance of common stock for consulting services	28.83K
Deferred rent	247.59K
Prepaids expenses and other current assets	1.5M
Research grant and other receivables
Inventory	-11.85M
Other assets	298.57K
Accounts payable and accrued expenses	3.64M
Net cash provided (used) in operating activities
Purchases of short-term investments
Sales or maturity of short-term investments	70.11K
Purchases of property and equipment	-605.17K
Net cash used by investing activities
Proceeds from sale of common stock	9.39M
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period	119.44M
Cash and cash equivalents at end of period	72.84M

Entities mentioned with OPTR

View All Entities